Depending on how one views it, the stock price performance for the year has been a mixed bag, resulting in either an optimistic or pessimistic outlook. The metric has seen a significant loss of -53.68% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -71.37%. Over the past 30 days, the price of ADAP has leaped by -45.37%. And in the last five days, it has surged by 10.59%.
Adaptimmune Therapeutics Plc ADR experienced a rather shaky stock market performance. The highest value in the past year was recorded at $1.48 on 07/30/24 and the lowest value was $0.20 on 04/01/25.
52-week price history of ADAP Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Adaptimmune Therapeutics Plc ADR’s current trading price is -83.14% away from its 52-week high, while its distance from the 52-week low is 27.88%. The stock’s price range during this period has varied between$0.20 and $1.48. The Adaptimmune Therapeutics Plc ADR’s shares, which operate in the Healthcare, saw a trading volume of around 0.99 million for the day, a figure considerably lower than their average daily volume of 1.68 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Adaptimmune Therapeutics Plc ADR (ADAP) has experienced a quarterly decline of -57.70% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 63.86M and boasts a workforce of 506 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.5227, with a change in price of -0.3455. Similarly, Adaptimmune Therapeutics Plc ADR recorded 1,946,385 in trading volume during the last 100 days, posting a change of -58.07%.
ADAP’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for ADAP stands at 6.26. Similarly, the long-term debt-to-equity ratio is also 5.86.
ADAP Stock Stochastic Average
As of today, Adaptimmune Therapeutics Plc ADR’s raw stochastic average for the last 50 days stands at 12.76%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 19.79%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 14.55% and 11.70%, respectively.
